Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ZYME stock hub

Zymeworks Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ZYMEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ZYME

In the news

Latest news · ZYME

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E21.2

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-42

P25 -105.6P50 -46.5P75 -3.1

ROIC-97.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ZYME market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

207

Groups with data

Currency

USD

Showing 207 of 207 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001403752
Company name	Zymeworks Inc.
Country	United States
Country code	US
Cusip	98985W102
Employees	264
Employees Change	-22%
Employees Change Percent	-7.69
Enterprise value	$1.4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-04-28
Isin	US98985Y1082
Last refreshed	2026-05-10
Market cap	$1.8B
Market cap category	Small-Cap
Price	$23.89
Price currency	USD
Rev Per Employee	307,814.39x
Sector	Healthcare
Sic	2834
Symbol	ZYME
Website	https://www.zymeworks.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.83%
EV/Sales	16.92x
FCF yield	-4.37%
Forward P/E	21.25x
P/B ratio	10.68x
P/S ratio	21.68x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-140.35%
EBITDA Margin	-132.64%
Gross margin	-67.01%
Gross Profit	$-54.5M
Net Income	$-102.7M
Net Income Growth Years	1%
Pretax Margin	-127.94%
Profit Margin	-126.33%
Profit Per Employee	$-388,848
ROA	-15.78
Roa5y	-11.23
ROCE	-25.77
ROE	-42.02
Roe5y	-22.56
ROIC	-97.68
Roic5y	-402.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	110.78%
Cagr3y	40.35%
Cagr5y	-4.64%
EPS Growth Years	2
Revenue Growth	-12.98x
Revenue Growth Q	-91.12x
Revenue Growth Years	2x
Revenue Growth3 Y	-43.31x
Revenue Growth5 Y	21x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.18
Assets	$478.2M
Cash	$364.7M
Current Assets	$385.7M
Current Liabilities	$35.6M
Debt	$17M
Debt Equity	$0.1
Equity	$163.6M
Interest Coverage	-55.21
Liabilities	$314.6M
Long Term Assets	$92.5M
Long Term Liabilities	$279M
Net Cash	$386.8M
Net Cash By Market Cap	$21.95
Net Cash Growth	27.6%
Net Debt Equity	$-2.36
Tangible Book Value	$150.4M
Tangible Book Value Per Share	$2.06
WACC	10.81

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.82
Net Working Capital	$-11.4M
Quick ratio	10.36
Working Capital	$350M
Working Capital Turnover	$0.27

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.41%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	110.67%
200-day SMA	21.35
3Y total return	176.51%
50-day SMA	25.69
50-day SMA vs 200-day SMA	50over200
5Y total return	-21.16%
All Time High	59.03
All Time High Change	-59.53%
All Time High Date	2021-01-12
All Time Low	4.11
All Time Low Change	481.27%
All Time Low Date	2022-09-07
ATR	1.28
Beta	1.19
Beta1y	0.23
Beta2y	1.05
Ch YTD	-9.27
High	26.21
High52	29.75
High52 Date	2026-04-27
High52ch	-19.7%
Low	23.39
Low52	10.86
Low52 Date	2025-05-08
Low52ch	119.98%
Ma50ch	-7.01%
Premarket Change Percent	-2.63
Premarket Price	$25.9
Premarket Volume	7,077
Price vs 200-day SMA	11.92%
RSI	35.08
RSI Monthly	62.01
RSI Weekly	52.1
Sharpe ratio	1.57x
Sortino ratio	2.99
Total Return	0.41%
Tr YTD	-9.27
Tr1m	-8.12%
Tr1w	-10.22%
Tr3m	5.15%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	4
Analyst Price Target Top	$41.75
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.1
Earnings Revenue Estimate	37,435,392x
Earnings Revenue Estimate Growth	38.09x
Operating Income	$-114.1M
Operating margin	-140.4
Price target	$39
Price Target Change	$63.25
Price Target Change Top	$74.76

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	68,820,877%
Float Percent	93.32%
Shares Insiders	1.29%
Shares Institutions	51.87%
Shares Out	73,749,607
Shares Qo Q	-0.85%
Shares Yo Y	-0.41%
Short Float	6.76%
Short Ratio	7.55
Short Shares	6.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-105.6M
Average Volume	560,284.95x
Bv Per Share	2.24
CAPEX	$-1.7M
Ch1m	-8.12
Ch1w	-10.22
Ch1y	110.7
Ch3m	5.15
Ch3y	176.5
Ch5y	-21.16
Ch6m	45.14
Change	-10.19%
Change From Open	-8.85
Close	26.6
Days Gap	-1.47
Depreciation Amortization	6,266,000
Dollar Volume	34,748,554.5
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-114.1M
EBITDA	$-107.8M
EPS	$-1.37
F Score	2
FCF	$-77M
FCF EV Yield	-5.6x
FCF Per Share	$-1.04
Financing CF	158,911,000
Fiscal Year End	December
Founded	2,003
Goodwill	12,016,000
Income Tax	$-1.3M
Investing CF	84,440,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Ma150	23.57
Ma150ch	1.36%
Ma20	27.31
Ma20ch	-12.51%
Net CF	168,078,000
Next Earnings Date	2026-08-06
Open	26.21
Optionable	Yes
Position In Range	17.73
Post Close	23.89
Postmarket Change Percent	0.51
Postmarket Price	$24.01
Ppne	28,870,000
Pre Close	26.6
Price Date	2026-05-08
Ptbv Ratio	11.71
Relative Volume	2.6x
Revenue	81,263,000x
SBC By Revenue	35.15x
Share Based Comp	28,567,000
Tax By Revenue	-1.61x
Tr6m	45.14%
Us State	Delaware
Volume	1,454,523
Z Score	-0.36

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ZYME pay a dividend?

Capital-return profile for this ticker.

Performance

ZYME stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ZYME?

Insider, institutional, and short-interest positioning.

Institutional ownership

+51.9%

Float: +93.3% of shares outstanding

Insider ownership

+1.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ZYME momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

35.1

Neutral momentum band

Price vs 200-day MA

+11.9%

50/200-day relationship not available

Beta (5Y)

1.19

Moves roughly with the market

Sharpe ratio

1.57

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ZYME

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ZYME stock rating?

Zymeworks Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZYME analysis?

The full report lives at /stocks/ZYME/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ZYME?

The latest report frames ZYME around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ZYME page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.